The DOI matches its Crossref record.
Abstract ND11: Discovery of GDC-6036, a clinical stage treatment for KRAS G12C-positive cancers
Abstract
Mutations in KRAS are the most common oncogenic driver mutations in human cancers. The KRAS G12C mutation is one of the most prevalent KRAS mutations, present in approximately 12% of non-small cell lung cancer, 4% of colorectal cancer, and up to 4% of other cancer types. The recent discovery and development of covalent KRAS G12C inhibitors provides an opportunity to inhibit what has historically been considered to be an “undruggable” target. GDC-6036 is an orally bioavailable, highly potent and selective KRAS G12C inhibitor, with a median IC50 in the sub-nanomolar range and greater than 18,000-fold selectivity for G12C versus non-G12C cell lines. GDC-6036 demonstrates greater potency and selectivity compared with other KRAS G12C inhibitors in vitro, and complete tumor growth inhibition in multiple KRAS G12C-positive cell lines and in xenograft mouse models. We will highlight the research program that led to the discovery and optimization of GDC-6036, which is currently in clinical development. Citation Format: Hans Purkey. Discovery of GDC-6036, a clinical stage treatment for KRAS G12C-positive cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr ND11.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In vitro studies have also shown that divarasib is 5 to 20 times as potent and up to 50 times as selective as compared to the KRAS G12C inhibitors sotorasib and adagrasib10.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [10]
In the citing paper
“Divarasib has been shown to be 5 to 20 times more potent in vitro as compared to sotorasib and adagrasib10.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [10]
Citations
Cites
Still being checked.
Cited by
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
Sacher, A., LoRusso, P., Patel, M. R., Miller, W. H., Garralda, E., Forster, M. D., Santoro, A., Falcon, A., Kim, T. W., Paz-Ares, L., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303810 · Cited by 328
A review: FDA-approved fluorine-containing small molecules from 2015 to 2022
Sheikhi, N., Bahraminejad, M., Saeedi, M., & Mirfazli, S. S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115758 · Cited by 148
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Desai, J., Alonso, G., Kim, S. H., Cervantes, A., Karasic, T., Medina, L., Shacham-Shmueli, E., Cosman, R., Falcon, A., Gort, E., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02696-8 · Cited by 144
“…by the small number of patients enrolled into this arm and the lack of comparison of this divarasib and cetuximab combination to a standard-of-care treatment in KRAS G12C -positive CRC. Divarasib has been shown to be 5 to 20 times more potent in vitro as compared to sotorasib and adagrasib 10 .”
BackgroundRecent Advances in Covalent Drug Discovery
Schaefer, D., & Cheng, X. (2023) · Pharmaceuticals · doi:10.3390/ph16050663 · Cited by 122
Lorthiois, E., Gerspacher, M., Beyer, K. S., Vaupel, A., Leblanc, C., Stringer, R., Weiss, A., Wilcken, R., Guthy, D. A., Lingel, A., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01438 · Cited by 110
Metadata
- Authors
- Purkey, H.
- Affiliations
- Genentech (US)
- Corresponding author
- Purkey, Hans
- ORCID
- Purkey, Hans
- Venue
- Cancer Research
- Published
- 2022-06-15
- Volume
- 82
- Issue
- 12_Supplement
- Pages
- ND11-ND11
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W4282972221
- Cited by
- 69
- References
- 0
- Citations by year
- 2026: 11 · 2025: 18 · 2024: 24 · 2023: 14 · 2022: 2
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- KRAS G12C, covalent KRAS inhibitor, KRAS mutation, non-small cell lung cancer, colorectal cancer, drug discovery, medication optimization, oral bioavailability, xenograft tumor growth inhibition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abstract ND11: Discovery of GDC-6036, a clinical stage treatment for KRAS G12C-positive cancers. https://app.cochat.ai/papers/10.1158/1538-7445.am2022-nd11
- The paper
- Purkey, H. (2022). Abstract ND11: Discovery of GDC-6036, a clinical stage treatment for KRAS G12C-positive cancers. Cancer Research. https://doi.org/10.1158/1538-7445.am2022-nd11
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.